glp 1 agonist fda approval just approved orforglipron (Foundayo), Eli Lilly's oral GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest New GLP-1 Pill Foundayo (Orforglipron)
Pay in 4 interest-free payments of $6.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



























